Sitagliptin 50mg + Metformin 1000mg + Glimepiride 1mg Tablets

Sitagliptin 50mg + Metformin 1000mg + Glimepride 1mg combines sitagliptin, glimepiride, and metformin for adults with type 2 diabetes for a three-drug oral regimen treatment. This treatment is for type 2 diabetes and is not used for type 1 diabetes or diabetic ketoacidosis. Patients should know low-glucose symptoms such as sweating, shaking, hunger, fast heartbeat, confusion, and unusual sleepiness, and should carry fast-acting sugar if advised.
Take Sitagliptin 50mg + Metformin 1000mg + Glimepride 1mg as prescribed, usually with meals. Do not skip meals after dosing. Monitor glucose as instructed and know how to treat low blood sugar.
Sitagliptin supports incretin signaling, glimepiride increases insulin release, and metformin reduces hepatic glucose production and improves insulin sensitivity.
Possible effects include low blood sugar, nausea, diarrhea, abdominal discomfort, headache, weight gain, and metallic taste. Serious concerns include severe hypoglycemia, lactic acidosis, pancreatitis, allergic swelling, severe joint pain, bullous pemphigoid, kidney problems, and heart-failure symptoms.
Review eGFR, meal pattern, hypoglycemia history, older age, alcohol use, liver disease, heart failure, dehydration, severe infection, contrast imaging, surgery, pancreatitis history, pregnancy, breastfeeding, and other diabetes medicines.
Type 2 diabetes mellitus in adults when sitagliptin, glimepiride, and metformin combination therapy is prescribed.
Targets post-meal glucose, insulin secretion, and liver glucose output in one regimen when dual therapy is not enough and hypoglycemia risk is managed.
Sitagliptin 50mg + Metformin 1000mg + Glimepride 1mg is used for type 2 diabetes when the prescriber wants sitagliptin, glimepiride, and metformin together.
The glimepiride component can cause hypoglycemia, especially with missed meals, alcohol, kidney impairment, or older age.
Meals reduce stomach upset from metformin and help lower the risk of glimepiride-related low glucose.
Sweating, shaking, hunger, fast heartbeat, confusion, headache, or unusual sleepiness should be treated as instructed.
Kidney function affects metformin safety, sitagliptin dose selection, and hypoglycemia risk.
Sitagliptin glimepiride metformin, Triple diabetes, DPP-4 sulfonylurea metformin, Hypoglycemia warning, Lactic acidosis risk, HbA1c monitoring, AR: Sitagliptin + Metformin + Glimepride أقراص, FR: Sitagliptin + Metformin + Glimepride comprimé, PT: Sitagliptin + Metformin + Glimepride comprimido, ES: Sitagliptin + Metformin + Glimepride tableta, RU: Sitagliptin + Metformin + Glimepride таблетки, ID: Sitagliptin + Metformin + Glimepride, VI: Sitagliptin + Metformin + Glimepride viên nén, MS: Sitagliptin + Metformin + Glimepride, TL: Sitagliptin + Metformin + Glimepride tableta, ZH-SG: Sitagliptin + Metformin + Glimepride 片剂
International B2B Enquiry
Send a structured B2B enquiry for Sitagliptin 50mg + Metformin 1000mg + Glimepiride 1mg Tablets under Diabetes Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Sitagliptin 50mg + Metformin 1000mg + Glimepiride 1mg Tablets